Exploring the path to selective TRK inhibition
Loxo Oncology breakthrough therapy larotrectinib demonstrates 76% confirmed objective response rate in TRK fusion adult and pediatric cancers as presented at the 2017 Annual Meeting of the American Society of Clinical Oncology®
June 3, 2017 | Press release> | Explore the latest data >
1. Hyman DM, et al. The efficacy of larotrectinib (LOXO-101), a selective tropomyosin receptor kinase (TKR) inhibitor, in adult and pediatric TRK fusion cancers. In: Proceedings from the 2017 ASCO Annual Meeting; June 2–6, 2017; Chicago, Illinois. Abstract LBA2501. 2. Laetsch TW, et al. A pediatric phase I study of larotrectinib, a highly selective inhibitor of the tropomyosin receptor kinase (TRK) family. In: Proceedings from the 2017 ASCO Annual Meeting; June 2–6, 2017; Chicago, Illinois. Abstract 10510.